Publications
*Includes seizure clusters and acute or prolonged seizures
146 result(s)
BRIVIACT® (brivaracetam) CV
Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: post-hoc analysis of a randomized, placebo-controlled trial
ZILBRYSQ® (zilucoplan)
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial
BIMZELX® (bimekizumab-bkzx)
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
BIMZELX® (bimekizumab-bkzx)
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
FINTEPLA® (fenfluramine)
Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial
FINTEPLA® (fenfluramine)
Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial
NAYZILAM® (midazolam) CIV
Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: an open-label extension trial
BRIVIACT® (brivaracetam) CV
Safety and tolerability of adjunctive brivaracetam in pediatric patients <16 years with epilepsy: an open-label trial
NAYZILAM® (midazolam) CIV
Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters - a randomized, double-blind, placebo-controlled trial
CIMZIA® (certolizumab pegol)
A 52-week randomized placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis.